Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $31.14

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus recommendation of “Buy” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $31.14.

Several research firms recently weighed in on CPRX. Stephens started coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th.

Insider Activity

In related news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now directly owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently bought and sold shares of CPRX. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the second quarter valued at about $258,000. Integral Health Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at about $4,260,000. GSA Capital Partners LLP purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $625,000. Capstone Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $708,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 146.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after buying an additional 217,956 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $21.74 on Friday. The business has a 50-day moving average of $21.48 and a two-hundred day moving average of $19.02. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of 18.42, a price-to-earnings-growth ratio of 3.36 and a beta of 0.75. Catalyst Pharmaceuticals has a 1 year low of $13.00 and a 1 year high of $24.27.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.